NCT05476211已完成不适用
Safety and Efficacy of the BTL-785F Device for Non-invasive Reduction of Wrinkles
BTL Industries Ltd.2 个研究点 分布在 1 个国家目标入组 46 人开始时间: 2022年3月31日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 46
- 试验地点
- 2
- 主要终点
- Assess reduction of wrinkle severity according to the Fitzpatrick Wrinkle and Elastosis Scale
研究概览
简要总结
This study will evaluate the clinical safety and the performance of the BTL-785F system for non-invasive treatment of facial wrinkles. The study is a multicenter single-arm, open-label, interventional study. The subjects will be enrolled and assigned into one experimental study arm. The subjects will be required to complete four (4) treatment visits and two follow-up visits.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy male or female subjects over 21 years of age seeking treatment for reduction of wrinkles
- •Subjects should be able understand the investigative nature of the treatment, the possible benefits and side effects, and must sign the Informed Consent Form
- •Presence of clearly visible wrinkles in the treated areas (forehead, cheeks) when the face is relaxed as deemed appropriate by the Investigator
- •Subjects willing and able to abstain from partaking in any facial treatments other than the study procedure during study participation
- •Willingness to comply with study instructions, to return to the clinic for the required visits, and to have photographs of their face taken
排除标准
- •Local bacterial or viral infection in the area to be treated
- •Local acute inflammation in the area to be treated
- •Impaired immune system caused by any immunosuppressive illness, disease or medication
- •Isotretinoin and tretinoin-containing medication use in the past 12 months
- •Skin related autoimmune diseases
- •Radiation therapy and/or chemotherapy
- •Poor healing and unhealed wounds in the treatment area
- •Metal implants
- •Permanent implant in the treated area
- •Pacemaker or internal defibrillator, or any other active electrical implant anywhere in the body
- •Facial dermabrasion, facial resurfacing, or deep chemical peeling in the treatment area within 3 months prior to the treatment
- •Current or history of skin cancer, or current condition of any other type of cancer, or pre-malignant moles
- •History of skin disorders, keloids, abnormal wound healing and dry or fragile skin
- •History of any type of cancer
- •Active collagen diseases
- •Cardiovascular diseases (such as vascular diseases, peripheral arterial disease, thrombophlebitis and thrombosis)1
- •Pregnancy/nursing or IVF procedure
- •History of bleeding coagulopathies, use of anticoagulants
- •Any active condition in the treatment area, such as sores, psoriasis, eczema, rash and rosacea
- •Any surgical procedure in the treatment area within the last three months or before complete healing
- •Poorly controlled endocrine disorders, such as diabetes
- •Acute neuralgia and neuropathy
- •Kidney or liver failure
- •Nerve insensitivity (sensitivity disorders) to heat in the treatment area
- •Varicose veins, pronounced edemas1
- •Prior use of dermal fillers, botulinum toxin, lasers, etc. therapies in the treated area that can influence the study results at the investigator discretion
- •Unwillingness/inability to not change their usual cosmetics and especially not to use anti-aging or anti-wrinkles products in the treated area during the duration of the study including the follow-up period
- •Electroanalgesia without exact diagnosis of pain etiology
- •Neurological disorders (such as multiple cerebrospinal sclerosis, epilepsy)
- •Blood vessels and lymphatic vessels inflammation
- •Any other disease or condition at the investigator discretion that may pose risk to the patient or compromise the study
结局指标
主要结局
Assess reduction of wrinkle severity according to the Fitzpatrick Wrinkle and Elastosis Scale
时间窗: 4 months
The primary efficacy outcome measure is a statistically significant reduction of at least 1.0 score in the average score of Fitzpatrick Wrinkle and Elastosis Scale score according to at least 2 out of 3 blinded dermatologists at 3-months follow-up compared to baseline.
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Safety and Efficacy of the BTL-785F Device for Non-invasive Reduction of Submental FatSkin LaxityNCT05831332BTL Industries Ltd.56
已完成
不适用
BTL-785F Device for Non-invasive Facial Rejuvenation in Patients Injected With Botulinum ToxinWrinkleNCT05524766BTL Industries Ltd.13
已完成
不适用
BTL-785F Device for Improving the Structure of Facial MusclesWrinkleNCT05524740BTL Industries Ltd.10
已完成
不适用
BTL-785F Device for Non-invasive Reduction of WrinklesWrinkleNCT05519124BTL Industries Ltd.20
已完成
不适用
Evaluation of Safety and Efficacy of the BTL-785F Device for Non-invasive Facial RemodelingWrinkleNCT05525026BTL Industries Ltd.24